A composition includes ashwagandha in a range of 5% to 20%; plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%; coffee fruit extract in a range of 0.5% to 10%; grape seed extract in a range of 1% to 10%; Cordyceps in a range of 5% to 20%; extended-release caffeine in a range of 0.5% to 10%; whole coffee fruit extract in a range of 1% to 10%; Schisandra extract in a range of 1% to 10%; L-theanine in a range of 1% to 10%; and beet juice in a range of 20% to 60%.

A composition includes ashwagandha in a range of 5% to 20%; plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%; coffee fruit extract in a range of 0.5% to 10%; grape seed extract in a range of 1% to 10%; Cordyceps in a range of 5% to 20%; extended-release caffeine in a range of 0.5% to 10%; whole coffee fruit extract in a range of 1% to 10%; Schisandra extract in a range of 1% to 10%; L-theanine in a range of 1% to 10%; and beet juice in a range of 20% to 60%.

Provided herein are compositions, formulations, kits, and methods for improving or modifying cognitive performance in an individual having normal-age related cognitive decline. The composition can include an amount of a blueberry extract, L-carnosine, a green tea extract, vitamin D.sub.3, and a grape extract. The composition can be included in a pharmaceutical formulation and be administered to a subject having normal-age related cognitive decline according to a dosing regimen.

Provided herein are compositions, formulations, kits, and methods for improving or modifying cognitive performance in an individual having normal-age related cognitive decline. The composition can include an amount of a blueberry extract, L-carnosine, a green tea extract, vitamin D.sub.3, and a grape extract. The composition can be included in a pharmaceutical formulation and be administered to a subject having normal-age related cognitive decline according to a dosing regimen.

Provided herein are compositions, formulations, kits, and methods for improving or modifying cognitive performance in an individual having normal-age related cognitive decline. The composition can include an amount of a blueberry extract, L-carnosine, a green tea extract, vitamin D.sub.3, and a grape extract. The composition can be included in a pharmaceutical formulation and be administered to a subject having normal-age related cognitive decline according to a dosing regimen.

The present invention relates to transgenic grape cells, compositions comprising such cells or extracts or fractions thereof, and methods of use thereof for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject. Disclosed herein are also methods for preventing, treating, reducing the incidence, suppressing or inhibiting a coronavirus infection or a symptom thereof.

The invention relates, in general, to healing formulations containing pomegranate seed oil, rosa canina fruit oil, and inula viscosa oleoresin or extract. In some instances the formulations may also contain citrus medica vulgaris etrog oil or extract and other ingredients. The healing formulations are all natural, do not include any artificial preservatives and are safe and effective for treating certain skin disorders and conditions.

The invention relates, in general, to healing formulations containing pomegranate seed oil, rosa canina fruit oil, and inula viscosa oleoresin or extract. In some instances the formulations may also contain citrus medica vulgaris etrog oil or extract and other ingredients. The healing formulations are all natural, do not include any artificial preservatives and are safe and effective for treating certain skin disorders and conditions.

A composition and method for treating Epidermolisis bullosa (EB), comprising: applying to skin or mucosal surfaces of a patient in need of treatment for EB a dressing gauze or bandage without prior cleaning of said skin or mucosal surfaces, wherein distributed on said dressing is an effective amount of a composition containing beeswax; an oleaginous base, vitamins and a pharmaceutically acceptable excipient; then removing said dressing at least twice per day without damaging the patient's skin or mucosal surfaces due to removal of the dressing.

A composition and method for treating Epidermolisis bullosa (EB), comprising: applying to skin or mucosal surfaces of a patient in need of treatment for EB a dressing gauze or bandage without prior cleaning of said skin or mucosal surfaces, wherein distributed on said dressing is an effective amount of a composition containing beeswax; an oleaginous base, vitamins and a pharmaceutically acceptable excipient; then removing said dressing at least twice per day without damaging the patient's skin or mucosal surfaces due to removal of the dressing.